Sands B E
MGH Crohn's and Colitis Center, Massachusetts General and Gastrointestinal Unit Hospital, 165 Cambridge St, 9th Floor, Boston, MA 02114, USA.
Gut. 2006 Apr;55(4):437-41. doi: 10.1136/gut.2005.078055.
Immunosuppressive drugs have become a mainstay of therapy for the inflammatory bowel diseases. Although robust evidence exists in support of the use of these drugs in Crohn's disease, a close evaluation of the available data in ulcerative colitis reveals a much weaker evidence base. In particular, randomised controlled trials of azathioprine, the most commonly used immunosuppressive agent, do not provide rich evidence of efficacy whereas observational cohorts suggest this agent is effective, particularly in patients with relapsing disease who require corticosteroids. Ciclosporin is also effective in the most refractory cases but its efficacy needs to be carefully weighed against the possibility of rare but life threatening complications. Although the evidence base in support of immunosuppressive drugs in ulcerative colitis is not as strong as in Crohn's disease, these agents clearly have a role in the treatment of this disease.
免疫抑制药物已成为炎症性肠病治疗的主要手段。尽管有充分证据支持在克罗恩病中使用这些药物,但对溃疡性结肠炎现有数据的仔细评估显示,证据基础要薄弱得多。特别是,最常用的免疫抑制剂硫唑嘌呤的随机对照试验并未提供充分的疗效证据,而观察性队列研究表明该药物是有效的,尤其是在需要使用皮质类固醇的复发型患者中。环孢素在最难治的病例中也有效,但其疗效需要与罕见但危及生命的并发症的可能性仔细权衡。尽管支持在溃疡性结肠炎中使用免疫抑制药物的证据基础不如在克罗恩病中那么有力,但这些药物在该疾病的治疗中显然有一定作用。